Lung cancer differential marker

Patent metadata

Field	Value
Publication number	US-10539576-B2
Application number	US-201715620214-A
Country	US
Kind code	B2
Filing date	Jun 12, 2017
Priority date	Sep 17, 2010
Publication date	Jan 21, 2020
Grant date	Jan 21, 2020

Abstract

An object of the present invention is to develop and provide a lung cancer differential marker with which lung cancer can be diagnosed conveniently and highly sensitively without depending only on increase or decrease in protein expression level between cancer patients and healthy persons. Another object of the present invention is to develop and provide a glycan marker capable of distinguishing histological types of lung cancer. Of serum glycoproteins, glycopeptide and glycoprotein groups whose glycan structures were altered specifically in lung cancer cell culture supernatants were identified, and they are provided as lung cancer differential markers.

First claim

We claim:

1. A method for determining whether a test subject afflicted with lung cancer is afflicted with adenocarcinoma comprising:
(i) detecting a lung cancer differential marker glycoprotein glycosylated with a glycan at an asparagine residue or at least one fragment thereof in a sample obtained from the test subject, and
(ii) determining whether the test subject is afflicted with adenocarcinoma by determining whether the glycoprotein or the fragment thereof is present in the sample;
wherein the presence of the glycoprotein or fragment in the sample indicates that the test subject is afflicted with adenocarcinoma, and the absence of the glycoprotein or fragment in the sample indicates that the test subject is not afflicted with adenocarcinoma, and wherein:
(a) the lung cancer differential marker glycoprotein is fibronectin 1, and the glycoprotein and the fragment thereof comprise the amino acid sequence;
(b) the lung cancer differential marker glycoprotein or the fragment thereof is detected using at least one glycan probe that binds to a fucosylated glycan or β1,3-galactose wherein the glycan probe is PNA lectin; and
(c) the sample is a body fluid, lung cancer tissue or a lung lavage.

2. The method of claim 1 , wherein the body fluid is pleural effusion, lymph, a cell extract, sputum, or blood comprising serum, plasma and interstitial fluid.

3. A method of distinguishing between small cell lung cancer and lung adenocarcinoma in a test subject afflicted with small cell lung cancer or lung adenocarcinoma, the method comprising:
(i) detecting binding of PNA lectin to a lung cancer differential marker glycoprotein or at least one fragment thereof in a sample obtained from the test subject by contacting the sample with the lectin, and
(ii) determining that the lung cancer in the test subject is lung adenocarcinoma if the glycoprotein or fragment thereof in the sample acquired from the test subject binds to PNA, or that the lung cancer in the test subject is small cell lung cancer if the glycoprotein or fragment thereof in the sample acquired from the test subject does not bind to PNA,
wherein the glycoprotein is fibronectin 1 and the glycoprotein and the fragment thereof comprise the amino acid sequence of SEQ ID NO: 19, wherein SEQ ID NO: 19 is glycosylated with a glycan at the asparagine residue at position 23;
and wherein the sample is a body fluid, lung cancer tissue or a lung lavage.

4. The method of claim 3 , wherein the body fluid is pleural effusion, lymph, a cell extract, sputum, or blood comprising serum, plasma and interstitial fluid.

Assignees

• Aist
• Univ Tokyo Medical

Inventors

• Narimatsu Hisashi
• Togayachi Akira
• Ikehara Yuzuru
• Kaji Hiroyuki
• Kuno Atsushi
• Ohkura Takashi
• Matsuzaki Hideki
• Hirao Yoshitoshi
• Iwaki Jun
• Abe Minako
• Nomura Masaharu
• Noguchi Masayuki

Classifications

• G01N33/575

  for cancer · CPC title

• G01N33/5752

  of the lungs · CPC title

• C07K14/4748 Primary

  Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE · CPC title

• G01N2440/38

  addition of carbohydrates, e.g. glycosylation, glycation · CPC title

• C07K16/28

  against receptors, cell surface antigens or cell surface determinants · CPC title